Sankyo Pharma Sets Up In UK
Japan's second largest drugmaker, Sankyo Pharmaceuticals, has now set upSankyo Pharma UK Ltd. This is the result of a name change for Panpharma Ltd, part of the Munich, Germany-based Luitpold Pharma Group which Sankyo acquired in 1989.
Sankyo says it is best known for such products as the lipid-lowerer pravastatin (marketed in the UK by Bristol-Myers Squibb as Lipostat) and cefpodoxime, an oral third-generation cephalosporin, which is currently sold by Panpharma and Hoechst Marion Roussel as Orelox.
Later this year, the new company will launch troglitazone (sold in Japan as Noscal), a Sankyo product for the management of type II diabetes, which has been codeveloped in Europe by Sankyo and Glaxo Wellcome. Sankyo Pharma will continue to focus on both ethical and over-the-counter products in the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze